Literature DB >> 10193524

Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.

L D Kozaci1, C J Brown, C Adcocks, A Galloway, A P Hollander, D J Buttle.   

Abstract

AIMS: To determine the collective roles of stromelysin 1, neutrophil collagenase, and collagenase 3 in chondrocyte mediated cartilage proteoglycan and type II collagen degradation in tissue culture model systems.
METHODS: Bovine nasal cartilage explants were cultured with and without recombinant human interleukin 1 alpha (IL-1 alpha), recombinant human tumour necrosis factor alpha, or retinoic acid. Proteoglycan and type II collagen release were determined by colorimetric assay and immunoassay, respectively, in the absence and presence of matrixin inhibitors. Potential toxic effects of the inhibitors were assessed by measuring rates of glycolysis.
RESULTS: Loss of proteoglycan and type II collagen from nasal cartilage was inhibited by batimastat, a broad spectrum matrixin inhibitor. BB-3437, a selective inhibitor of stromelysin, neutrophil collagenase, and collagenase 3, at the concentrations used in this study, showed a weak but dose dependent inhibitory effect on the IL-1 stimulated degradation of type II collagen, but had virtually no effect on proteoglycan breakdown. Neither inhibitor affected rates of glycolysis.
CONCLUSIONS: Stromelysin 1, neutrophil collagenase, and collagenase 3 are unlikely to contribute to chondrocyte mediated proteoglycan degradation in our model system. The modest effect of a selective inhibitor of these enzymes on IL-1 stimulated collagen breakdown suggests a minor role for one or more of these proteinases; potent inhibition by an inhibitor of interstitial collagenase and the gelatinases suggests that these enzymes play a major role in IL-1 stimulated, chondrocyte mediated type II collagen breakdown from nasal cartilage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10193524      PMCID: PMC395653          DOI: 10.1136/mp.51.5.282

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  38 in total

1.  Neutral metallo-proteinases of rabbit bone. Separation in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans.

Authors:  A Sellers; J J Reynolds; M C Meikle
Journal:  Biochem J       Date:  1978-05-01       Impact factor: 3.857

2.  Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage.

Authors:  J J Wu; M W Lark; L E Chun; D R Eyre
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

3.  Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures.

Authors:  L D Kozaci; D J Buttle; A P Hollander
Journal:  Arthritis Rheum       Date:  1997-01

4.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.

Authors:  B Davies; P D Brown; N East; M J Crimmin; F R Balkwill
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

5.  Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture.

Authors:  T E Cawston; A J Ellis; G Humm; E Lean; D Ward; V Curry
Journal:  Biochem Biophys Res Commun       Date:  1995-10-04       Impact factor: 3.575

6.  A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro.

Authors:  H J Andrews; T A Plumpton; G P Harper; T E Cawston
Journal:  Agents Actions       Date:  1992-09

7.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

8.  Inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by a lipophilic inactivator of cysteine endopeptidases.

Authors:  D J Buttle; J Saklatvala; M Tamai; A J Barrett
Journal:  Biochem J       Date:  1992-01-01       Impact factor: 3.857

9.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.

Authors:  P G Mitchell; H A Magna; L M Reeves; L L Lopresti-Morrow; S A Yocum; P J Rosner; K F Geoghegan; J E Hambor
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay.

Authors:  A P Hollander; T F Heathfield; C Webber; Y Iwata; R Bourne; C Rorabeck; A R Poole
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more
  4 in total

1.  Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases.

Authors:  T G Morgan; A D Rowan; S C Dickinson; D Jones; A P Hollander; D Deehan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

2.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Authors:  R L Van Bezooijen; L Van Der Wee-Pals; S E Papapoulos; C W G M Löwik
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

3.  Combining stretching and gallic acid to decrease inflammation indices and promote extracellular matrix production in osteoarthritic human articular chondrocytes.

Authors:  Haneen A Abusharkh; Olivia M Reynolds; Juana Mendenhall; Bulent A Gozen; Edwin Tingstad; Vincent Idone; Nehal I Abu-Lail; Bernard J Van Wie
Journal:  Exp Cell Res       Date:  2021-09-24       Impact factor: 4.145

Review 4.  Matrix metalloproteinases in arthritic disease.

Authors:  Gillian Murphy; Vera Knäuper; Susan Atkinson; George Butler; William English; Mike Hutton; Jan Stracke; Ian Clark
Journal:  Arthritis Res       Date:  2002-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.